Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension / Benza, Raymond L; Langleben, David; Hemnes, Anna R; Vonk Noordegraaf, Anton; Rosenkranz, Stephan; Thenappan, Thenappan; Hassoun, Paul M; Preston, Ioana R; Ghio, Stefano; Badagliacca, Roberto; Vizza, Carmine D; Lang, Irene M; Meier, Christian; Grünig, Ekkehard. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 0905-9180. - 31:166(2022). [10.1183/16000617.0061-2022]

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Benza, Raymond L
;
Badagliacca, Roberto;Vizza, Carmine D;
2022

Abstract

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.
2022
riociguat; right ventricle; pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension
01 Pubblicazione su rivista::01a Articolo in rivista
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension / Benza, Raymond L; Langleben, David; Hemnes, Anna R; Vonk Noordegraaf, Anton; Rosenkranz, Stephan; Thenappan, Thenappan; Hassoun, Paul M; Preston, Ioana R; Ghio, Stefano; Badagliacca, Roberto; Vizza, Carmine D; Lang, Irene M; Meier, Christian; Grünig, Ekkehard. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 0905-9180. - 31:166(2022). [10.1183/16000617.0061-2022]
File allegati a questo prodotto
File Dimensione Formato  
Benza_Riociguat_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 592.98 kB
Formato Adobe PDF
592.98 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1670173
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact